Tvardi Therapeutics, Inc. (TVRD)
1.82
+0.04
(+2.25%)
USD |
NASDAQ |
Aug 27, 15:01
Tvardi Therapeutics Enterprise Value : 1.079M for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 1.079M |
| August 25, 2026 | 1.454M |
| August 24, 2026 | 1.079M |
| August 21, 2026 | 1.829M |
| August 20, 2026 | 1.548M |
| August 19, 2026 | 2.017M |
| August 18, 2026 | 2.204M |
| August 17, 2026 | 1.829M |
| August 14, 2026 | 2.204M |
| August 13, 2026 | 0.9849M |
| August 12, 2026 | 0.9849M |
| August 11, 2026 | 0.9849M |
| August 10, 2026 | 0.8911M |
| August 07, 2026 | 1.923M |
| August 06, 2026 | 1.735M |
| August 05, 2026 | 3.143M |
| August 04, 2026 | 3.424M |
| August 03, 2026 | 3.330M |
| July 31, 2026 | 4.081M |
| July 30, 2026 | 4.081M |
| July 29, 2026 | 4.456M |
| July 28, 2026 | 7.270M |
| July 27, 2026 | 8.208M |
| July 24, 2026 | 7.927M |
| July 23, 2026 | 8.396M |
| Date | Value |
|---|---|
| July 22, 2026 | 10.27M |
| July 21, 2026 | 11.21M |
| July 20, 2026 | 11.87M |
| July 17, 2026 | 14.40M |
| July 16, 2026 | 13.27M |
| July 15, 2026 | 11.87M |
| July 14, 2026 | 13.46M |
| July 13, 2026 | 15.43M |
| July 10, 2026 | 15.15M |
| July 09, 2026 | 20.03M |
| July 08, 2026 | 31.29M |
| July 07, 2026 | 13.46M |
| July 06, 2026 | 3.236M |
| July 02, 2026 | 3.330M |
| July 01, 2026 | 2.674M |
| June 30, 2026 | 2.204M |
| June 29, 2026 | -6.889M |
| June 26, 2026 | -10.74M |
| June 25, 2026 | -2.667M |
| June 24, 2026 | -2.761M |
| June 23, 2026 | -2.104M |
| June 22, 2026 | 0.3349M |
| June 18, 2026 | -0.1342M |
| June 17, 2026 | -0.6032M |
| June 16, 2026 | -0.1342M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.166T |
| Nektar Therapeutics | 1.969B |
| Crinetics Pharmaceuticals, Inc. | 7.818B |
| Liquidia Corp. | 6.257B |
| ANI Pharmaceuticals, Inc. | 1.947B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.457M |
| Total Expenses (Quarterly) | 6.457M |
| EPS Diluted (Quarterly) | -0.6883 |
| Earnings Yield | -152.7% |
| Normalized Earnings Yield | -152.66 |